Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study
Loggers E, Chugh R, Federman N, Hartner L, Riedel R, Cho S, Hyslop D, Lim A, Oton A, Oktay K. Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study. Cancer 2024, 130: 2812-2821. PMID: 38703010, DOI: 10.1002/cncr.35324.Peer-Reviewed Original ResearchFemales of reproductive potentialFollicle-stimulating hormoneReturn of menstruationOvarian toxicityDesmoid tumorsFollow-upContinuous 28-day cyclesLost to follow-upPhase 3 studyProgressive desmoid tumorsPost hoc analysisSafety populationNirogacestatStopping treatmentHormone valuesSafety signalsHoc analysisPatientsPerimenopausal symptomsMenstruationGamma-secretase inhibitorsPlaceboRandom femalesTumorEvent follow-up